Lee, Erinna F.
Harris, Tiffany J.
Tran, Sharon
Evangelista, Marco
Arulananda, Surein
John, Thomas
Ramnac, Celeste
Hobbs, Chloe
Zhu, Haoran
Gunasingh, Gency
Segal, David
Behren, Andreas http://orcid.org/0000-0001-5329-280X
Cebon, Jonathan
Dobrovic, Alexander
Mariadason, John M.
Strasser, Andreas
Rohrbeck, Leona
Haass, Nikolas K. http://orcid.org/0000-0002-3928-5360
Herold, Marco J.
Fairlie, W. Douglas
Funding for this research was provided by:
Worldwide Cancer Research (15-0025, 15-0025, 15-0025, 15-0025)
Victorian Cancer Agency (TRP13041, TRP13041, TRP13041, TRP13041)
Department of Education and Training | Australian Research Council (FT150100212)
Department of Health | National Health and Medical Research Council (1016701,1020363, 1145728,1143105)
Article History
Received: 12 November 2018
Revised: 28 February 2019
Accepted: 2 April 2019
First Online: 24 April 2019
Conflict of interest
: The Walter and Eliza Hall Institute has previously been involved in collaborations with Abbvie and Genentech to develop and characterize BH3-mimetic drugs. The Institute and some authors have or may receive payments in respect of Venetoclax. The Walter and Eliza Hall Institute also has an on-going collaboration with Servier to investigate the use of MCL-1 inhibitors for cancer therapy.